Increased aquaglyceroporin 9 expression disrupts arsenic resistance in human lung cancer cells

Toxicology in Vitro

Volumn 23, Issue 2, 2009, Pages 209-216

  Miao, Zhi Feng ^a   Chang, Eddy Essen ^a   Tsai, Feng Yuan ^a   Yeh, Szu Ching ^a   Wu, Chia Fang ^a   Wu, Kuen Yuh ^a   Wang, Chien Jen ^a   Tsou, Tsui Chun ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Aquaglyceroporins; Arsenic resistance; Arsenic transporters; Human lung cancer

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; AQUAGLYCEROPORIN; AQUAGLYCEROPORIN 9; ARSENIC TRIOXIDE; MILVETEROL; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; AQUAGLYCEROPORIN 9 GENE; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; LUNG CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

ANTINEOPLASTIC AGENTS; AQUAPORINS; ARSENICALS; CELL LINE, TUMOR; DEOXYGUANOSINE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; HUMANS; LUNG NEOPLASMS; OXIDES;

EID: 59249084681     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2008.11.011     Document Type: Article

References (73)

1. Agre P., and Kozono D. Aquaporin water channels: molecular mechanisms for human diseases. FEBS Lett. 555 (2003) 72-78
2. Aposhian H.V. Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu. Rev. Pharmacol. Toxicol. 37 (1997) 397-419
3. Bhattacharjee H., Carbrey J., Rosen B.P., and Mukhopadhyay R. Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. Biochem. Biophys. Res. Commun. 322 (2004) 836-841
4. Cabon J.Y. Effects of various salts on the determination of arsenic by graphite furnace atomic absorption spectrometry. Direct determination in seawater. Fresenius J. Anal. Chem. 367 (2000) 714-721
5. Carter N.S., and Fairlamb A.H. Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 361 (1993) 173-176
6. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88 (1996) 1052-1061
7. Chen Z., Chen G.Q., Shen Z.X., Chen S.J., and Wang Z.Y. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin. Hematol. 38 (2001) 26-36
8. Conrad M.E. Treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 340 (1999) 1043-1045
9. Ding W., Hudson L.G., and Liu K.J. Inorganic arsenic compounds cause oxidative damage to DNA and protein by inducing ROS and RNS generation in human keratinocytes. Mol. Cell. Biochem. 279 (2005) 105-112
10. Engel R.R., Hopenhayn-Rich C., Receveur O., and Smith A.H. Vascular effects of chronic arsenic exposure: a review. Epidemiol. Rev. 16 (1994) 184-209
11. Erhola M., Toyokuni S., Okada K., Tanaka T., Hiai H., Ochi H., Uchida K., Osawa T., Nieminen M.M., Alho H., and Kellokumpu-Lehtinen P. Biomarker evidence of DNA oxidation in lung cancer patients: association of urinary 8-hydroxy-2′-deoxyguanosine excretion with radiotherapy, chemotherapy, and response to treatment. FEBS Lett. 409 (1997) 287-291
12. Gallagher R.E. Arsenic - new life for an old potion. N. Engl. J. Med. 339 (1998) 1389-1391
13. Han B., Zhou G., Zhang Q., Zhang J., Wang X., Tang W., and Kakudo K. Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp. J. Exp. Ther. Oncol. 4 (2004) 335-342
14. Helbock H.J., Beckman K.B., Shigenaga M.K., Walter P.B., Woodall A.A., Yeo H.C., and Ames B.N. DNA oxidation matters: the HPLC-electrochemical detection assay of 8-oxo-deoxyguanosine and 8-oxo-guanine. Proc. Natl. Acad. Sci. USA 95 (1998) 288-293
15. Ho I.C., and Lee T.C. Arsenite pretreatment attenuates benzo[a]pyrene cytotoxicity in a human lung adenocarcinoma cell line by decreasing cyclooxygenase-2 levels. J. Toxicol. Environ. Health A 65 (2002) 245-263
16. Hu C.W., Wu M.T., Chao M.R., Pan C.H., Wang C.J., Swenberg J.A., and Wu K.Y. Comparison of analyses of urinary 8-hydroxy-2′-deoxyguanosine by isotope-dilution liquid chromatography with electrospray tandem mass spectrometry and by enzyme-linked immunosorbent assay. Rapid Commun. Mass Spectrom. 18 (2004) 505-510
17. Huang R.N., and Lee T.C. Cellular uptake of trivalent arsenite and pentavalent arsenate in KB cells cultured in phosphate-free medium. Toxicol. Appl. Pharmacol. 136 (1996) 243-249
18. Huff J., Chan P., and Nyska A. Is the human carcinogen arsenic carcinogenic to laboratory animals?. Toxicol. Sci. 55 (2000) 17-23
19. Huppa J.B., and Ploegh H.L. The eS-Sence of -SH in the ER. Cell 92 (1998) 145-148
20. IARC. Arsenic and arsenic compounds. IARC Monogr. Eval. Carcinog. Risk Chem. Hum. 23 (1980) 39-141
21. Jiang T.T., Brown S.L., and Kim J.H. Combined effect of arsenic trioxide and sulindac sulfide in A549 human lung cancer cells in vitro. J. Exp. Clin. Cancer Res. 23 (2004) 259-262
22. Kala S.V., Neely M.W., Kala G., Prater C.I., Atwood D.W., Rice J.S., and Lieberman M.W. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J. Biol. Chem. 275 (2000) 33404-33408
23. Keppler D. Export pumps for glutathione S-conjugates. Free Radical Biol. Med. 27 (1999) 985-991
24. Lee T.C., and Ho I.C. Expression of heme oxygenase in arsenic-resistant human lung adenocarcinoma cells. Cancer Res. 54 (1994) 1660-1664
25. Lee T.C., Ho I.C., Lu W.J., and Huang J.D. Enhanced expression of multidrug resistance-associated protein 2 and reduced expression of aquaglyceroporin 3 in an arsenic-resistant human cell line. J. Biol. Chem. 281 (2006) 18401-18407
26. Leslie E.M., Haimeur A., and Waalkes M.P. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J. Biol. Chem. 279 (2004) 32700-32708
27. Leung J., Pang A., Yuen W.H., Kwong Y.L., and Tse E.W. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood 109 (2007) 740-746
28. Li W., and Chou I.N. Effects of sodium arsenite on the cytoskeleton and cellular glutathione levels in cultured cells. Toxicol. Appl. Pharmacol. 114 (1992) 132-139
29. Li M., Cai J.F., and Chiu J.F. Arsenic induces oxidative stress and activates stress gene expressions in cultured lung epithelial cells. J. Cell. Biochem. 87 (2002) 29-38
30. Li H.C., Wang C.X., Huang C., Wang L.F., Mu X.Y., Jiang S.J., and Lei M.L. Effect and mechanism of arsenic trioxide on chemosensitivity of human lung adenocarcinoma cells. Zhonghua Jie He He Hu Xi Za Zhi 26 (2003) 689-692
31. Li C.S., Wu K.Y., Chang-Chien G.P., and Chou C.C. Analysis of oxidative DNA damage 8-hydroxy-2′-deoxyguanosine as a biomarker of exposures to persistent pollutants for marine mammals. Environ. Sci. Technol. 39 (2005) 2455-2460
32. Lin H.S., Jenner A.M., Ong C.N., Huang S.H., Whiteman M., and Halliwell B. A high-throughput and sensitive methodology for the quantification of urinary 8-hydroxy-2′-deoxyguanosine: measurement with gas chromatography-mass spectrometry after single solid-phase extraction. Biochem. J. 380 (2004) 541-548
33. Lin L.M., Li B.X., Xiao J.B., Lin D.H., and Yang B.F. Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells in vitro. World J. Gastroenterol. 11 (2005) 5633-5637
34. Ling Y.H., Jiang J.D., Holland J.F., and Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol. Pharmacol. 62 (2002) 529-538
35. Liu Z., Shen J., Carbrey J.M., Mukhopadhyay R., Agre P., and Rosen B.P. Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc. Natl. Acad. Sci. USA 99 (2002) 6053-6058
36. Liu Z., Carbrey J.M., Agre P., and Rosen B.P. Arsenic trioxide uptake by human and rat aquaglyceroporins. Biochem. Biophys. Res. Commun. 316 (2004) 1178-1185
37. Liu Z., Styblo M., and Rosen B.P. Methylarsonous acid transport by aquaglyceroporins. Environ. Health Perspect. 114 (2006) 527-531
38. Look A.T. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia. J. Natl. Cancer Inst. 90 (1998) 86-88
39. Mei N., Kunugita N., Hirano T., and Kasai H. Acute arsenite-induced 8-hydroxyguanine is associated with inhibition of repair activity in cultured human cells. Biochem. Biophys. Res. Commun. 297 (2002) 924-930
40. Mervis J. Ancient remedy performs new tricks. Science 273 (1996) 578
41. Miller Jr. W.H., Schipper H.M., Lee J.S., Singer J., and Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 62 (2002) 3893-3903
42. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
43. Ochi T. Arsenic compound-induced increases in glutathione levels in cultured Chinese hamster V79 cells and mechanisms associated with changes in gamma-glutamylcysteine synthetase activity, cystine uptake and utilization of cysteine. Arch. Toxicol. 71 (1997) 730-740
44. Park M.J., Park I.C., Bae I.J., Seo K.M., Lee S.H., Hong S.I., Eun C.K., Zhang W., and Rhee C.H. Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor. Int. J. Oncol. 22 (2003) 1271-1276
45. Piao F., Ma N., Hiraku Y., Murata M., Oikawa S., Cheng F., Zhong L., Yamauchi T., Kawanishi S., and Yokoyama K. Oxidative DNA damage in relation to neurotoxicity in the brain of mice exposed to arsenic at environmentally relevant levels. J. Occup. Health 47 (2005) 445-449
46. Powis G., Briehl M., and Oblong J. Redox signalling and the control of cell growth and death. Pharmacol. Ther. 68 (1995) 149-173
47. Rahman M., Tondel M., Ahmad S.A., Chowdhury I.A., Faruquee M.H., and Axelson O. Hypertension and arsenic exposure in Bangladesh. Hypertension 33 (1999) 74-78
48. Ravanat J.L., Douki T., Duez P., Gremaud E., Herbert K., Hofer T., Lasserre L., Saint-Pierre C., Favier A., and Cadet J. Cellular background level of 8-oxo-7,8-dihydro-2′-deoxyguanosine: an isotope based method to evaluate artefactual oxidation of DNA during its extraction and subsequent work-up. Carcinogenesis 23 (2002) 1911-1918
49. Robles A.I., Linke S.P., and Harris C.C. The p53 network in lung carcinogenesis. Oncogene 21 (2002) 6898-6907
50. Rosen B.P. Biochemistry of arsenic detoxification. FEBS Lett. 529 (2002) 86-92
51. Shen Z.Y., Shen J., Li Q.S., Chen C.Y., Chen J.Y., and Yi Z. Morphological and functional changes of mitochondria in apoptotic esophageal carcinoma cells induced by arsenic trioxide. World J. Gastroenterol. 8 (2002) 31-35
52. Shi Y., Liu Y., Huo J., and Gao G. Arsenic trioxide induced apoptosis and expression of p53 and bcl-2 genes in human small cell lung cancer cells. Zhonghua Jie He He Hu Xi Za Zhi 25 (2002) 665-666
53. Shi M., Takeshita H., Komatsu M., Xu B., Aoyama K., and Takeuchi T. Generation of 8-hydroxydeoxyguanosine from DNA using rat liver homogenates. Cancer Sci. 96 (2005) 13-18
54. Slack J.L., and Rusiniak M.E. Current issues in the management of acute promyelocytic leukemia. Ann. Hematol. 79 (2000) 227-238
55. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D.A., Pandolfi P.P., and Warrell Jr. R.P. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339 (1998) 1341-1348
56. Srivenugopal K.S., Shou J., Mullapudi S.R., Lang Jr. F.F., Rao J.S., and Ali-Osman F. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin. Cancer Res. 7 (2001) 1398-1409
57. Styblo M., Drobna Z., Jaspers I., Lin S., and Thomas D.J. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ. Health Perspect. 110 Suppl. 5 (2002) 767-771
58. Tagesson C., Kallberg M., Klintenberg C., and Starkhammar H. Determination of urinary 8-hydroxydeoxyguanosine by automated coupled-column high performance liquid chromatography: a powerful technique for assaying in vivo oxidative DNA damage in cancer patients. Eur. J. Cancer 31A (1995) 934-940
59. Thomas D.J., Waters S.B., and Styblo M. Elucidating the pathway for arsenic methylation. Toxicol. Appl. Pharmacol. 198 (2004) 319-326
60. Tseng C.H., Chong C.K., Chen C.J., and Tai T.Y. Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Atherosclerosis 120 (1996) 125-133
61. Tseng C.H., Tai T.Y., Chong C.K., Tseng C.P., Lai M.S., Lin B.J., Chiou H.Y., Hsueh Y.M., Hsu K.H., and Chen C.J. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ. Health Perspect. 108 (2000) 847-851
62. Tsou T.C., Yeh S.C., Tsai F.Y., and Chang L.W. The protective role of intracellular GSH status in the arsenite-induced vascular endothelial dysfunction. Chem. Res. Toxicol. 17 (2004) 208-217
63. Vernhet L., Allain N., Bardiau C., Anger J.P., and Fardel O. Differential sensitivities of MRP1-overexpressing lung tumor cells to cytotoxic metals. Toxicology 142 (2000) 127-134
64. Vernhet L., Allain N., Payen L., Anger J.P., Guillouzo A., and Fardel O. Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide. Biochem. Pharmacol. 61 (2001) 1387-1391
65. Viktorsson K., De Petris L., and Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem. Biophys. Res. Commun. 331 (2005) 868-880
66. Wang Z.Y., and Chen Z. Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia. Lancet Oncol. 1 (2000) 101-106
67. Wang H.F., and Lee T.C. Glutathione S-transferase pi facilitates the excretion of arsenic from arsenic-resistant Chinese hamster ovary cells. Biochem. Biophys. Res. Commun. 192 (1993) 1093-1099
68. Wang Z., Dey S., Rosen B.P., and Rossman T.G. Efflux-mediated resistance to arsenicals in arsenic-resistant and -hypersensitive Chinese hamster cells. Toxicol. Appl. Pharmacol. 137 (1996) 112-119
69. Warrell Jr. R.P. Arsenicals and inhibitors of histone deacetylase as anticancer therapy. Haematologica 84 Suppl. EHA-4 (1999) 75-77
70. Waters S.B., Devesa V., Fricke M.W., Creed J.T., Styblo M., and Thomas D.J. Glutathione modulates recombinant rat arsenic (+3 oxidation state) methyltransferase-catalyzed formation of trimethylarsine oxide and trimethylarsine. Chem. Res. Toxicol. 17 (2004) 1621-1629
71. Wei L., Wang X.W., and Zuo W.S. Toxicity of arsenic trioxide to human lung adenocarcinoma cell line SPCA1 and its mechanism. Ai Zheng 23 (2004) 1633-1638
72. Yang P.C., Luh K.T., Wu R., and Wu C.W. Characterization of the mucin differentiation in human lung adenocarcinoma cell lines. Am. J. Respir. Cell. Mol. Biol. 7 (1992) 161-171
73. Zaman G.J., Lankelma J., van Tellingen O., Beijnen J., Dekker H., Paulusma C., Oude Elferink R.P., Baas F., and Borst P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. USA 92 (1995) 7690-7694